<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04745273</url>
  </required_header>
  <id_info>
    <org_study_id>SevgiB</org_study_id>
    <nct_id>NCT04745273</nct_id>
  </id_info>
  <brief_title>Interaction Between Tramadol and Ondansetron</brief_title>
  <official_title>The Effect of Ondansetron on the Efficacy of Tramadol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acibadem University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acibadem University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the postoperative period; pain, nausea, and vomiting are undesirable side effects that&#xD;
      reduce the patient's comfort and may lead to various complications. Ondansetron is frequently&#xD;
      used as an antiemetic and tramadol hydrochloride is used for postoperative analgesia in&#xD;
      laparoscopic cholecystectomy. However, some studies have reported that there is a drug&#xD;
      interaction between these two drugs and they reduce each other's effects, thus requiring more&#xD;
      analgesics in the postoperative period.&#xD;
&#xD;
      The aim of this study is; To evaluate whether ondansetron reduces the analgesic efficacy of&#xD;
      tramadol hydrochloride in laparoscopic cholecystectomies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During the operation, 4 mg iv ondansetron (2mL) will be administered to the ondansetron group&#xD;
      and 2mL iv 09% saline will be administered to the placebo group. The patients' heart rate,&#xD;
      blood pressure, oxygen saturation, sedation score (with Ramsey Seading Score), amount of pain&#xD;
      (with NRS), degree of nausea (with NRS), whether there is vomiting, whether analgesic or&#xD;
      antiemetic treatment is required, and the amount of tramadol use will be recorded at 1, 2, 4,&#xD;
      8, 12 and 24 hours in the postoperative period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Interaction</measure>
    <time_frame>24 hours</time_frame>
    <description>The hypothesis of this study is that if ondanstron is given together with tramadol peroperatively, tramadol consumption is increase postoperatively due to tramadol ondansetron interaction. The primary outcome measure is consumption of tramadol postoperatively for 24 hours.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cholecystectomy, Laparoscopic</condition>
  <arm_group>
    <arm_group_label>Ondansetron</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive Kemoset 4 mg iv intraoperatively</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Salin solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive Salin solution 2ml (iv) intraoperatively</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron 4 MG (Kemoset 4mg)</intervention_name>
    <description>Ondansetron 4mg (iv) will administer to participants</description>
    <arm_group_label>Ondansetron</arm_group_label>
    <other_name>Kemoset</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Salin solution</intervention_name>
    <description>Salin solution 2ml (iv) will administer to participants</description>
    <arm_group_label>Salin solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        60 patients over the age of 18, ASA I-II, undergoing laparoscopic cholecystectomy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients under 18 years of age&#xD;
&#xD;
          2. Patients with known allergies to the drugs to be used&#xD;
&#xD;
          3. Pregnant and breastfeeding mothers&#xD;
&#xD;
          4. Patients who received antiemetic or cortisone within 24 hours before surgery&#xD;
&#xD;
          5. Patients with mental illness or epilepsy&#xD;
&#xD;
          6. Patients with alcohol or substance abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sevgi Bilgen, Assoc. Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Anethesiologist</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sevgi Bilgen, Assoc. prof.</last_name>
    <phone>0905324316401</phone>
    <email>sevgibilgen@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Acibadem Kozyatagi Hastanesi</name>
      <address>
        <city>Istanbul</city>
        <zip>(_34742__) ______</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Acibadem Kozyatagi Hastanesi</last_name>
      <phone>0902165714444</phone>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 31, 2021</study_first_submitted>
  <study_first_submitted_qc>February 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 9, 2021</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Acibadem University</investigator_affiliation>
    <investigator_full_name>Sevgi Bilgen</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>tramadol</keyword>
  <keyword>ondansetron</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ondansetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

